Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 31

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical and Translational Research

World J Clin Cases. Nov 6, 2022; 10(31): 11299-11312
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11299

Table 2 The traditional Chinese medicine monomers confirmed or predicted having ribonucleotide reductase M2 inhibition in tumors

Name	In vivo study	In vitro study	Bioinformatics analysis
Berberine	-	Non-small cell lung cancer	Breast cancer
Ursolic acid	-	-	Hepatoma, Colon cancer
Gambogic acid	Pancreatic cancer	Pancreatic cancer	-
Cinobufagin	Endometrial carcinoma	Endometrial carcinoma	-
Quercetin	-	-	Hepatoma, Colon cancer
Daphnetin	-	-	-
Osalmide	Esophageal Cancer, Multiple myeloma, Hepatocellular carcinoma, Diffuse large B-cell lymphoma	Esophageal Cancer, Multiple myeloma, Hepatocellular carcinoma, Diffuse large B-cell lymphoma	Multiple myeloma, Hepatocellular carcinoma

Citation: Qin YY, Feng S, Zhang XD, Peng B. Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment. World J Clin Cases 2022; 10(31): 11299-11312
URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11299.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11299

Qin YY, Feng S, Zhang XD, Peng B. Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment. World J Clin Cases 2022; 10(31): 11299-11312 [PMID: 36387821 DOI: 10.12998/wjcc.v10.i31.11299]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.